NASDAQ:KRYS

Krystal Biotech Stock Forecast, Price & News

$67.96

-3.21 (-4.51 %)

(As of 01/27/2021 12:21 PM ET)

Add

Compare

Today's Range

$66.40

Now: $67.96▼

$69.51

50-Day Range

$54.88

MA: $62.76▼

$73.00

52-Week Range

$33.08

Now: $67.96▼

$74.48

Volume6,693 shs

Average Volume120,513 shs

Market Capitalization$1.34 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.2

Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

MarketRank^™

Overall MarketRank^™

1.53 out of 5 stars

Medical Sector

382nd out of 1,925 stocks

Biological Products, Except Diagnostic Industry

47th out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $97.25, Krystal Biotech has a forecasted upside of 45.6% from its current price of $66.79.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Krystal Biotech has received 242 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Krystal Biotech has received 241 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Krystal Biotech has received 50.10% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote “Outperform” if you believe KRYS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 27.40% of the stock of Krystal Biotech is held by insiders.
Percentage Held by Institutions
73.05% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to decrease in the coming year, from ($1.74) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -45.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -45.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KRYS

Previous Symbol

CUSIPN/A

CIK1711279

Webwww.krystalbio.com

Phone412-586-5830

Employees51

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio39.96

Quick Ratio39.96

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$11.72 per share

Price / Book5.80

Profitability

EPS (Most Recent Fiscal Year)($1.20)

Net Income$-19,090,000.00

Net MarginsN/A

Return on Equity-10.72%

Return on Assets-10.40%

Miscellaneous

Outstanding Shares19,708,000

Market Cap$1.34 billion

Next Earnings Date3/9/2021 (Estimated)

OptionableNot Optionable

$67.96

-3.21 (-4.51 %)

(As of 01/27/2021 12:21 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

How has Krystal Biotech's stock been impacted by Coronavirus (COVID-19)?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KRYS stock has increased by 35.9% and is now trading at $67.86.
View which stocks have been most impacted by COVID-19.

Is Krystal Biotech a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Krystal Biotech?

Wall Street analysts have given Krystal Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Krystal Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings results on Saturday, November, 14th. The company reported ($0.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.02.
View Krystal Biotech's earnings history.

What price target have analysts set for KRYS?

5 brokerages have issued 12 month price objectives for Krystal Biotech's stock. Their forecasts range from $84.00 to $115.00. On average, they anticipate Krystal Biotech's share price to reach $97.25 in the next twelve months. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for Krystal Biotech or view Wall Street analyst' top-rated stocks.

Who are some of Krystal Biotech's key competitors?

Some companies that are related to Krystal Biotech include Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), SpringWorks Therapeutics (SWTX), Immunovant (IMVT), Ablynx (ABLYF), Editas Medicine (EDIT), Kymera Therapeutics (KYMR), bluebird bio (BLUE), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Revolution Medicines (RVMD), AlloVir (ALVR) and NantKwest (NK).
View all of KRYS's competitors.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:

Mr. Krish S. Krishnan, Chairman, Pres & CEO (Age 56, Pay $365.73k)
Ms. Suma M. Krishnan, Founder, COO & Director (Age 56, Pay $305.64k)
Ms. Pooja Agarwal, Sr. VP of Product Devel. (Age 42, Pay $259.58k)
Ms. Gloria Lin, Accounting Mang.
Ms. Kathryn A. Romano, Chief Accounting Officer (Age 40)
Mr. J. Christopher Naftzger, Chief Legal Officer & Corp. Sec. (Age 54)
Mr. John Karakkal, VP of North American Sales and Marketing
Ms. Katherine Tuminello, HR & Office Mang.
Mr. Josh Suskin, Director of HR & Operations
Ms. Whitney Glad Ijem, Sr. VP of Strategy & Bus. Devel.

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.11%), Liberty One Investment Management LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Krystal Biotech or view top insider-selling stocks.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and Liberty One Investment Management LLC.
View insider buying and selling activity for Krystal Biotech or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $67.86.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $1.34 billion. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 51 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here